Irwin Simon, Chief Executive Officer, Tilray Brands, stated, “Tilray’s trading levels have appreciated in recent weeks following President Trump’s review of cannabis rescheduling. We believe this ...

Results from the Phase 1 trial of ATH-1105 demonstrated a favorable safety and tolerability profile as well as dose-proportional pharmacokinetics and CNS penetration. ATH-1105 has also demonstrated ...

NEW YORK and AMSTERDAM, Aug. 14, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective ...

Published a post-hoc analysis of new data from the EscharEx Phase II trial in Advances in Wound Care, a peer-reviewed journal, providing clinical evidence that wound bed preparation is a key predictor ...

Traws to host a Q2 2025 business update call today, August 14th at 8:30 AM ET ...

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to sparing cancer patients further hardship by protecting their ears against the profound threat of cisplatin-induced ...

The Company intends to explore all available legal remedies against former officers of SRx Canada ...

Denovo Biopharma LLC is a clinical-stage biopharmaceutical company that uses novel biomarker approaches to execute efficient clinical trials in targeted patient subpopulations to increase the ...

The presentation can be followed as a live webcast accessed through a link on www.zelluna.com at 09:00 CET on Wednesday, August 20, 2025. The webcast presentation will be available on the Zelluna ...

During the fourth quarter of 2025, Werewolf plans to release interim data from the monotherapy and combination expansion arms, including tolerability, response rate, and durability for patients with ...

Strengthened Balance Sheet With $65.1 Million Public Offering: In July 2025, Larimar announced a public offering of common stock with net proceeds of $65.1 million supported by existing and new ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...